The convergence of major financial entities and specialized life science consulting firms highlights a structural dynamic where market forces directly shape investment priorities in the pharmaceutical sector. The linkage between R&D complexity and specific investments like QuartzBio suggests that market inefficiencies or high-risk areas in life science consulting are being capitalized upon by large institutional players. This pattern points to how financial capital seeks to enter complex, high-b...